Tonix Pharmaceuticals Holding Corp. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of common stock in a public offering. The company intends to use the net proceeds from the offering for working capital and general corporate purposes, the build out of the company’s manufacturing and research and development facilities, and the acquisition or licensing of approved products and products in development. A.G.P./Alliance Global Partners is acting as lead placement agent for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNXP:
- Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering
- Tonix Pharmaceuticals Announces Proposed Public Offering
- Tonix updates enrollment in Phase 2 UPLIFT Study of TNX-601 ER for MDD
- Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test
- Tonix Pharmaceuticals announces data on TNX-601 ER, TNX-4300